Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments

JL Mega, T Simon - The Lancet, 2015 - thelancet.com
Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010

M Hanssen, Y Cottin, K Khalife, L Hammer, P Goldstein… - Heart, 2012 - heart.bmj.com
Aim of FAST-MI 2010 To gather data on characteristics, management and outcomes of
patients hospitalised for acute myocardial infarction (AMI) at the end of 2010 in France …

[HTML][HTML] Genetic determinants of response to clopidogrel and cardiovascular events

T Simon, C Verstuyft, M Mary-Krause… - New England journal …, 2009 - Mass Medical Soc
Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

JL Mega, T Simon, JP Collet, JL Anderson, EM Antman… - Jama, 2010 - jamanetwork.com
Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

L Beaugerie, N Brousse, AM Bouvier, JF Colombel… - The Lancet, 2009 - thelancet.com
Background Reports of an increased risk of lymphoproliferative disorders in patients
receiving thiopurines for inflammatory bowel disease are controversial. We assessed this …

Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week

HGC Van Spall, A Lala, TF Deering, B Casadei… - Journal of the American …, 2021 - jacc.org
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic …

JL Mega, SL Close, SD Wiviott, L Shen, JR Walker… - The Lancet, 2010 - thelancet.com
Background Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by
ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C→ T, may affect …

Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice

C Combadière, S Potteaux, M Rodero, T Simon… - Circulation, 2008 - Am Heart Assoc
Background—Monocytes are critical mediators of atherogenesis. Deletion of individual
chemokines or chemokine receptors leads to significant but only partial inhibition of lesion …

[HTML][HTML] Polypill strategy in secondary cardiovascular prevention

JM Castellano, SJ Pocock, DL Bhatt… - … England Journal of …, 2022 - Mass Medical Soc
Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …

Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction

E Puymirat, T Simon, PG Steg, F Schiele, P Gueret… - Jama, 2012 - jamanetwork.com
Context The contemporary decline in mortality reported in patients with ST-segment
elevation myocardial infarction (STEMI) has been attributed mainly to improved use of …